首頁 > 市場調查報告書 > 製藥

孤兒藥

市場調查報告書

商品編碼

1469861

全球孤兒藥市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global Orphan Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年04月01日 | 出版商:

Value Market Research | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球孤兒藥市場需求預計將從 2023 年的 1,949.5 億美元達到近 3,620.4 億美元的市場規模，2024-2032 年研究期間複合年成長率為 7.12%。

孤兒藥是一種為治療影響少數人的罕見疾病或病症而生產的藥物。由於患者群體有限以及藥物開發和商業化的挑戰，製藥公司往往需要更多地關注這些疾病。這些藥物，包括延長專利保護、稅收抵免和加速核准流程，獲得特殊的監管激勵和市場獨佔權，以鼓勵其成長。

市場動態

罕見疾病和病症的日益普及以及基因研究和診斷技術的進步推動了對針對特定基因突變或罕見疾病的孤兒藥的需求。此外，衛生當局授予的監管獎勵措施和孤兒藥稱號，例如美國的《孤兒藥法案》和其他國家的類似法規，鼓勵製藥公司投資於孤兒藥的研發。此外，越來越多的罕見疾病患者倡導和支持團體正在提高人們的意識並倡導獲得孤兒藥，從而推動需求並促進市場成長。此外，生物技術和藥物開發技術的進步，例如基因治療、細胞療法和精準醫學方法，使得能夠開發出具有更高療效和安全性的創新孤兒藥物療法。

此外，孤兒藥治療的醫療保健支出和保險覆蓋範圍不斷增加，加上個人化醫療和基於價值的醫療保健模式的日益接受，為孤兒藥製造商創造了有利的市場條件。此外，製藥公司、學術機構和研究組織之間的策略合作和夥伴關係促進創新並加速孤兒藥的開發和商業化。然而，來自替代療法的日益激烈的競爭和有限的患者使用可能會挑戰未來幾年孤兒藥市場的成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球孤兒藥市場的各個細分市場進行了包容性評估。孤兒藥產業的成長和趨勢為本研究提供了整體方法。

市場區隔

孤兒藥市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助戰略家確定相應產品或服務的目標人群以及即將到來的機會。

依疾病類型

腫瘤學
胃腸道
肺部
神經病學
血液學
心血管
代謝紊亂
內分泌科
傳染性疾病
其他

按指標

生物製劑
非生物

按配銷通路

醫院藥房
專業藥房
零售藥局
其他

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲孤兒藥市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。孤兒藥市場的主要參與者包括諾華公司、百時美施貴寶公司、新基公司、羅氏有限公司、輝瑞公司、賽諾菲公司、亞力兄製藥公司、禮來公司、諾和製藥公司Nordisk A/ S、阿斯特捷利康公司、衛材有限公司、第一三共有限公司、拜耳公司、葛蘭素史克公司、默克公司、強生公司。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：孤兒藥公司的競爭格局

孤兒藥市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

頂級公司市佔率分析
市場集中度
Novartis AG

公司簡介
公司收入
產品
最近的發展

Bristol-Myers Squibb Company

公司簡介
公司收入
產品
最近的發展

Celgene Corporation

公司簡介
公司收入
產品
最近的發展

F. Hoffmann-La Roche Ltd.

公司簡介
公司收入
產品
最近的發展

Pfizer Inc.

公司簡介
公司收入
產品
最近的發展

Sanofi SA

公司簡介
公司收入
產品
最近的發展

Alexion Pharmaceuticals Inc.

公司簡介
公司收入
產品
最近的發展

Eli Lilly And Company

公司簡介
公司收入
產品
最近的發展

Novo Nordisk A/S

公司簡介
公司收入
產品
最近的發展

AstraZeneca Plc

公司簡介
公司收入
產品
最近的發展

Eisai Co. Ltd.

公司簡介
公司收入
產品
最近的發展

Daiichi Sankyo Company Limited

公司簡介
公司收入
產品
最近的發展

Bayer AG

公司簡介
公司收入
產品
最近的發展

GlaxoSmithKline Plc

公司簡介
公司收入
產品
最近的發展

Merck & Co. Inc.

公司簡介
公司收入
產品
最近的發展

Johnson & Johnson

公司簡介
公司收入
產品
最近的發展

註 - 在公司概況中，財務詳細資料和最新進展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR112114268

The global demand for Orphan Drugs Market is presumed to reach the market size of nearly USD 362.04 Billion by 2032 from USD 194.95 Billion in 2023 with a CAGR of 7.12% under the study period 2024 - 2032.

Orphan drugs are pharmaceutical medications created to treat rare diseases or conditions impacting a small number of individuals. Pharmaceutical companies often need to pay more attention to these diseases due to their limited patient populations and drug development and commercialization challenges. These drugs, including extended patent protection, tax credits, and accelerated approval processes, receive special regulatory incentives and market exclusivity to encourage their growth.

MARKET DYNAMICS

The increasing prevalence of rare diseases and disorders and advances in genetic research and diagnostic technologies drive the demand for orphan drugs targeting specific genetic mutations or rare conditions. Additionally, regulatory incentives and orphan drug designations granted by health authorities, such as the Orphan Drug Act in the United States and similar regulations in other countries, encourage pharmaceutical companies to invest in the research and development of orphan drugs. Furthermore, the growing patient advocacy and support groups for rare diseases are raising awareness and advocating for access to orphan drugs, driving demand and facilitating market growth. Moreover, advancements in biotechnology and drug development techniques, such as gene therapy, cell therapy, and precision medicine approaches, enable the development of innovative orphan drug therapies with improved efficacy and safety profiles.

Additionally, the increasing healthcare expenditure and insurance coverage for orphan drug treatments, combined with the growing acceptance of personalized medicine and value-based healthcare models, create favorable market conditions for orphan drug manufacturers. Furthermore, strategic collaborations and partnerships between pharmaceutical companies, academic institutions, and research organizations foster innovation and accelerate the development and commercialization of orphan drugs. However, increasing competition from alternative therapies and limited patient access may challenge the growth of the orphan drugs market in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of orphan drugs. The growth and trends of orphan drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the orphan drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Disease Type

Oncology
Gastrointestinal
Pulmonary
Neurology
Hematology
Cardiovascular
Metabolic Disorders
Endocrinology
Infectious Diseases
Others

By Indicator

Biologic
Non-Biologic

By Distribution Channel

Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Orphan Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Orphan Drugs market include Novartis AG, Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd., Pfizer, Inc., Sanofi S.A., Alexion Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk A/S, AstraZeneca plc, Eisai Co., Ltd., Daiichi Sankyo Company Limited, Bayer AG, GlaxoSmithKline plc, Merck & Co., Inc., Johnson & Johnson. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. ORPHAN DRUGS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Disease Type
- 3.7.2 Market Attractiveness Analysis By Indicator
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL ORPHAN DRUGS MARKET ANALYSIS BY DISEASE TYPE

5.1. Overview By Disease Type
5.2. Historical and Forecast Data
5.3. Analysis By Disease Type
5.4. Oncology Historic and Forecast Sales By Regions
5.5. Gastrointestinal Historic and Forecast Sales By Regions
5.6. Pulmonary Historic and Forecast Sales By Regions
5.7. Neurology Historic and Forecast Sales By Regions
5.8. Hematology Historic and Forecast Sales By Regions
5.9. Cardiovascular Historic and Forecast Sales By Regions
5.10. Metabolic Disorders Historic and Forecast Sales By Regions
5.11. Endocrinology Historic and Forecast Sales By Regions
5.12. Infectious Diseases Historic and Forecast Sales By Regions
5.13. Others Historic and Forecast Sales By Regions

6. GLOBAL ORPHAN DRUGS MARKET ANALYSIS BY INDICATOR

6.1. Overview By Indicator
6.2. Historical and Forecast Data
6.3. Analysis By Indicator
6.4. Biologic Historic and Forecast Sales By Regions
6.5. Non-biologic Historic and Forecast Sales By Regions

7. GLOBAL ORPHAN DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

7.1. Overview By Distribution Channel
7.2. Historical and Forecast Data
7.3. Analysis By Distribution Channel
7.4. Hospital Pharmacies Historic and Forecast Sales By Regions
7.5. Specialty Pharmacies Historic and Forecast Sales By Regions
7.6. Retail Pharmacies Historic and Forecast Sales By Regions
7.7. Others Historic and Forecast Sales By Regions

8. GLOBAL ORPHAN DRUGS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE ORPHAN DRUGS COMPANIES

9.1. Orphan Drugs Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF ORPHAN DRUGS INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Novartis AG
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Bristol-Myers Squibb Company
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Celgene Corporation
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. F. Hoffmann-La Roche Ltd.
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Pfizer Inc.
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Sanofi S.A.
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Alexion Pharmaceuticals Inc.
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Eli Lilly And Company
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Novo Nordisk A/S
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. AstraZeneca Plc
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
10.13. Eisai Co. Ltd.
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments
10.14. Daiichi Sankyo Company Limited
- 10.14.1 Company Overview
- 10.14.2 Company Revenue
- 10.14.3 Products
- 10.14.4 Recent Developments
10.15. Bayer AG
- 10.15.1 Company Overview
- 10.15.2 Company Revenue
- 10.15.3 Products
- 10.15.4 Recent Developments
10.16. GlaxoSmithKline Plc
- 10.16.1 Company Overview
- 10.16.2 Company Revenue
- 10.16.3 Products
- 10.16.4 Recent Developments
10.17. Merck & Co. Inc.
- 10.17.1 Company Overview
- 10.17.2 Company Revenue
- 10.17.3 Products
- 10.17.4 Recent Developments
10.18. Johnson & Johnson
- 10.18.1 Company Overview
- 10.18.2 Company Revenue
- 10.18.3 Products
- 10.18.4 Recent Developments